X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (186) 186
hematology (125) 125
index medicus (113) 113
female (110) 110
male (103) 103
middle aged (94) 94
aged (80) 80
adult (78) 78
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (73) 73
oncology (73) 73
chronic myelogenous leukemia (71) 71
imatinib mesylate (67) 67
treatment outcome (56) 56
imatinib (49) 49
benzamides (48) 48
chronic myeloid leukemia (46) 46
leukemia, myelogenous, chronic, bcr-abl positive - genetics (45) 45
pyrimidines - therapeutic use (45) 45
chronic myeloid-leukemia (44) 44
antineoplastic agents - therapeutic use (41) 41
piperazines - therapeutic use (40) 40
prognosis (34) 34
fusion proteins, bcr-abl - genetics (32) 32
aged, 80 and over (31) 31
protein kinase inhibitors - therapeutic use (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
dasatinib (30) 30
cancer (29) 29
hemic and lymphatic diseases (29) 29
adolescent (28) 28
disease-free survival (28) 28
follow-up studies (28) 28
life sciences (28) 28
pyrimidines - adverse effects (28) 28
interferon (27) 27
leukemia, myelogenous, chronic, bcr-abl positive - mortality (27) 27
therapy (27) 27
bcr-abl (26) 26
leukemia (26) 26
abridged index medicus (25) 25
cml (25) 25
follow-up (25) 25
hematology, oncology and palliative medicine (25) 25
piperazines - adverse effects (25) 25
antineoplastic agents - administration & dosage (24) 24
piperazines - administration & dosage (24) 24
pyrimidines - administration & dosage (24) 24
leukemia, myelogenous, chronic, bcr-abl positive - pathology (23) 23
antineoplastic agents - adverse effects (22) 22
interferon-alpha (22) 22
medical and health sciences (22) 22
medicin och hälsovetenskap (22) 22
remission induction (22) 22
survival (22) 22
immunology (21) 21
leukemia, myeloid, chronic-phase - drug therapy (21) 21
prospective studies (21) 21
survival analysis (21) 21
survival rate (20) 20
time factors (19) 19
tyrosine kinase inhibitor (19) 19
young adult (19) 19
mice (18) 18
research (18) 18
protein kinase inhibitors - administration & dosage (17) 17
retrospective studies (17) 17
risk factors (17) 17
animals (16) 16
care and treatment (16) 16
child (16) 16
clinical trials (16) 16
leukemia, myelogenous, chronic, bcr-abl positive - therapy (16) 16
chronic-phase (15) 15
clinical medicine (15) 15
klinisk medicin (15) 15
nilotinib (15) 15
transplantation (15) 15
analysis (14) 14
drug therapy (14) 14
protein-tyrosine kinases - antagonists & inhibitors (14) 14
tyrosine kinase inhibitors (14) 14
antineoplastic agents (13) 13
chemotherapy (13) 13
cytarabine - administration & dosage (13) 13
diagnosis (13) 13
kaplan-meier estimate (13) 13
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (13) 13
leukemia, myelogenous, chronic, bcr-abl positive - enzymology (13) 13
philadelphia-chromosome (13) 13
stem-cell transplantation (13) 13
combined modality therapy (12) 12
disease progression (12) 12
karyotyping (12) 12
mesylate (12) 12
protein kinase inhibitors - adverse effects (12) 12
resistance (12) 12
translocation, genetic (12) 12
tyrosine (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
bone-marrow-transplantation (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1029 - 1035
Journal Article
Blood, ISSN 0006-4971, 02/2017, Volume 129, Issue 7, pp. 846 - 854
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 6, pp. 872 - 884
Journal Article
Cancer, ISSN 0008-543X, 05/2017, Volume 123, Issue 10, pp. 1791 - 1799
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 424 - 430
Journal Article
JAMA, ISSN 0098-7484, 12/2017, Volume 318, Issue 21, pp. 2099 - 2110
Journal Article
Journal Article
Blood, ISSN 0006-4971, 04/2019, Volume 133, Issue 14, pp. 1520 - 1521
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2511 - 2521
In this study, adding pegylated interferon alfa-2a to imatinib therapy for chronic myeloid leukemia resulted in a greater reduction in the number of cells... 
CHRONIC MYELOGENOUS LEUKEMIA | CHROMOSOME | MEDICINE, GENERAL & INTERNAL | INTERFERON | CML | ABL TYROSINE KINASE | HEMATOPOIETIC STEM-CELLS | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | QUIESCENT | CYTARABINE | Piperazines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Proto-Oncogene Proteins c-abl - analysis | Cytarabine - adverse effects | Recombinant Proteins | RNA, Neoplasm - analysis | Adult | Female | Transcription, Genetic | Neutropenia - chemically induced | Proto-Oncogene Proteins c-abl - genetics | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Anemia - chemically induced | Treatment Outcome | Thrombocytopenia - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Stem Cells - drug effects | Interferon-alpha - adverse effects | Benzamides | Drug therapy | Chronic myeloid leukemia | Medical research | Kinases | Leukemia | Manuscripts
Journal Article
Haematologica, ISSN 0390-6078, 06/2019, Volume 104, Issue 6, pp. 1096 - 1098
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 10, pp. 917 - 927
Journal Article